Covid19
Conditions
Brief summary
The primary objective is to measure the change between COVID-19 patients and normal subjects; the secondary objective is to measure the change in COVID-19 patients between baseline and 4-month follow up.
Interventions
DEVICEuEXPLORER/mCT
Each participant will undergo two 18F-FDG PET/CT scans, one at baseline and one at 4- month (+/- 2 weeks) follow-up.
Sponsors
University of California, Davis
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* COVID-19 positive patients will have a previous positive COVID-19 test and radiographic findings, and/or a positive SARS-CoV-2 antibody test and be in early recovery. * First PET/CT visit needs to be within 8 weeks of COVID-19 diagnosis. * Ability to understand and willingness to sign an informed consent form. * Ability to adhere to the study visit schedule and other protocol requirements. * All persons ≥18 years of age.
Exclusion criteria
* Pregnant or lactating women. * Any condition that would prohibit the understanding or rendering of informed consent. * Unable to lie supine for 1-hour imaging with PET. * Prisoners. * Any comorbidity that, in the opinion of the investigator, could compromise protocol objectives.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| BAB permeability assessed | 1 imaging visit up to 60 minutes | Evaluating if there is a change in BAB permeability assessed by lung FDG K1 for patients with COVID 19 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 4 month follow-up PET/CT scan | 1 imaging visit up to 60 minutes | Evaluate the change in the scans between baseline scan and 4-month follow-up scan by assessing the pulmonary blood-air barrier permeability to glucose |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORGuobao Wang, PhD
University of California, Davis
Outcome results
None listed